文献速递骨软组织肉瘤与黑色素瘤

转移性黑色素瘤免疫检查点抑制剂治疗失败后的化疗:一项回顾性多中心分析

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
PubMed 文献 · Eur J Cancer · 2021-12-21

该回顾性多中心分析纳入24个黑色素瘤中心的463例免疫检查点抑制剂进展后接受化疗的转移性黑色素瘤患者,2007至2017年间治疗。作者认为化疗在转移性黑色素瘤治疗中作用有限。

要点

  • 单药紫杉类(N=40)客观缓解率25%,中位无进展生存期3.9个月。
  • 化疗后再次接受检查点抑制剂治疗缓解率16%,中位无进展生存期19.1个月。

核心结论

  • 化疗在检查点抑制剂治疗失败的转移性黑色素瘤患者中缓解率低、无进展生存期短,但不同方案间活性存在差异。
  • 化疗在转移性黑色素瘤治疗中作用有限。

研究设计与样本

  • 回顾性多中心分析,从24个黑色素瘤中心识别免疫检查点抑制剂进展后接受化疗的转移性黑色素瘤患者。
  • 共463例患者,治疗时间为2007年至2017年。
  • 评估客观缓解率、无进展生存期、总生存期和安全性。

主要发现

  • 56%的患者在化疗前接受过以PD-1为基础的治疗。
  • 化疗方案包括卡铂+紫杉醇(32%)、达卡巴嗪(25%)、替莫唑胺(15%)、紫杉类(9%,其中白蛋白结合型紫杉醇4%)、福莫司汀(6%)和其他(13%)。
  • 中位治疗持续时间为7.9周(0-108)。
  • 缓解情况包括完全缓解0.4%、部分缓解12%、疾病稳定21%和疾病进展67%。
  • 中位无进展生存期为2.6个月(2.2,3.0),缓解者的中位无进展生存期为8.7个月(6.3,16.3)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite remarkably improved outcomes with immune checkpoint inhibition, many patients with metastatic melanoma will eventually require further therapy. Chemotherapy has limited activity when used first-line but can alter the tumour microenvironment and does improve efficacy when used in combination with immunotherapy in lung cancer. Whether chemotherapy after checkpoint inhibitor failure has relevant activity in patients with metastatic melanoma is unknown. METHODS: Patients with metastatic melanoma treated with chemotherapy after progression on immunotherapy with checkpoint inhibitors were identified retrospectively from 24 melanoma centres. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and safety were examined. RESULTS: In total, 463 patients were treated between 2007 and 2017. Fifty-six per cent had received PD-1-based therapy before chemotherapy. Chemotherapy regimens included carboplatin + paclitaxel (32%), dacarbazine (25%), temozolomide (15%), taxanes (9%, nab-paclitaxel 4%), fotemustine (6%) and others (13%). Median duration of therapy was 7.9 weeks (0-108). Responses included 0.4% complete response (CR), 12% partial response (PR), 21% stable disease (SD) and 67% progressive disease (PD). Median PFS was 2.6 months (2.2, 3.0), and median PFS in responders was 8.7 months (6.3, 16.3), respectively. Twelve-month PFS was 12% (95% CI 2-15%). In patients who had received anti-PD-1 before chemotherapy, the ORR was 11%, and median PFS was 2.5 months (2.1, 2.8). The highest activity was achieved with single-agent taxanes (N = 40), with ORR 25% and median PFS 3.9 months (2.1, 6.2). Median OS from chemotherapy start was 7.1 months (6.5, 8.0). Subsequent treatment with checkpoint inhibitors achieved a response rate of 16% with a median PFS of 19.1 months (2.0-43.1 months). No unexpected toxicities were observed. CONCLUSION: Chemotherapy has a low response rate and short PFS in patients with metastatic melanoma who have failed checkpoint inhibitor therapy, although activity varied between regimens. Chemotherapy has a limited role in the management of metastatic melanoma.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Goldinger SM, Buder-Bakhaya K, Lo SN, et al. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer. 2021. PMID: 34952480. doi:10.1016/j.ejca.2021.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。